Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: A HuGE review

American Journal of Epidemiology

Volumn 165, Issue 3, 2007, Pages 235-245

  Olson, Sara H ^a   Bandera, Elisa V ^b   Orlow, Irene ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Androgens; CYP11A1; CYP17A1; CYP19A1; Endometrial neoplasms; Epidemiology; HSD17B; HSD3B

Indexed keywords

ANDROGEN; CYTOCHROME P450; CYTOCHROME P450 11A1; CYTOCHROME P450 17A1; CYTOCHROME P450 19A1; ESTROGEN; HYDROXYSTEROID DEHYDROGENASE; HYDROXYSTEROID DEHYDROGENASE 1; PROGESTERONE; SEX HORMONE; UNCLASSIFIED DRUG;

CANCER; EPIDEMIOLOGY; ESTROGENIC COMPOUND; ETIOLOGY; GENE; GENETIC ANALYSIS; GENETIC VARIATION; RISK FACTOR; SEX HORMONE;

ALLELE; CANCER RISK; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; EXON; GENE DELETION; GENE INSERTION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; METABOLISM; MOLECULAR INTERACTION; REVIEW; RISK REDUCTION; SEX HORMONE DETERMINATION; STEROID BLOOD LEVEL;

17-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; AROMATASE; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; CYTOCHROME P-450 ENZYME SYSTEM; ENDOMETRIAL NEOPLASMS; ESTRADIOL DEHYDROGENASES; ESTROGENS; FEMALE; GENOTYPE; GONADAL STEROID HORMONES; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGESTERONE; STEROID 17-ALPHA-HYDROXYLASE; VARIATION (GENETICS);

EID: 33846622810     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwk015     Document Type: Review

References (91)

1. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295-308.
2. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
3. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425-32.
4. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-35.
5. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-43.
6. Johnson MM, Houck J, Chen C. Screening for deleterious nonsynonymous single-nucleotide polymorphisms in genes involved in steroid hormone metabolism and response. Cancer Epidemiol Biomarkers Prev 2005;14:1326-9.
7. Jose M, Puche C, Cabero A, et al. Expression of P450c17 messenger ribonucleic acid in postmenopausal human ovary tissues. Fertil Steril 1999;71:528-35.
8. Nagamani M, Urban RJ. Expression of messenger ribonucleic acid encoding steroidogenic enzymes in postmenopausal ovaries. J Soc Gynecol Investig 2003;10:37-40.
9. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-6.
10. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, et al. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59:2825-8.
11. Loukola A, Chadha M, Penn SG, et al. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur J Hum Genet 2004;12:321-32.
12. Skibola CF, Bracci PM, Paynter RA, et al. Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 2005;14: 2391-401.
13. Thomas JL, Mason JI, Brandt S, et al. Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem 2002; 277:42795-801.
14. Rhee HS, Oh SH, Ko BJ, et al. Expression of 3beta-hydroxysteroid dehydrogenase and P450 side chain cleavage enzyme in the human uterine endometrium. Exp Mol Med 2003;35: 160-6.
15. Tsai SJ, Wu MH, Lin CC, et al. Regulation of steroidogenic acute regulatory protein expression and progesterone production in endometriotic stromal cells. J Clin Endocrinol Metab 2001;86:5765-73.
16. Devgan SA, Henderson BE, Yu MC, et al. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ ethnic groups: implications for prostate cancer risk. Prostate 1997;33:9-12.
17. Verreault H, Dufort I, Simard J, et al. Dinucleotide repeat polymorphisms in the HSD3B2 gene. Hum Mol Genet 1994; 3:384.
18. Bulun SE, Simpson ER. Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab 1994;78:428-32.
19. Simpson ER, Michael MD, Agarwal VR, et al. Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB J 1997;11:29-36.
20. Bulun SE, Economos K, Miller D, et al. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab 1994;79:1831-4.
21. Watanabe K, Sasano H, Harada N, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol 1995;146:491-500.
22. Berstein L, Zimarina T, Kovalevskij A, et al. CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease. Neoplasma 2005; 52:115-18.
23. Fowler JM, Ramirez N, Cohn DE, et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol 2005;192:1262-71; discussion 71-3.
24. Haiman CA, Hankinson SE, Spiegelman D, et al. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:215-16.
25. Tofteng CL, Kindmark A, Brandstrom H, et al. Polymorphisms in the CYP19 and AR genes-relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study. Calcif Tissue Int 2004;74:25-34.
26. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999;79:456-63.
27. Paynter RA, Hankinson SE, Colditz GA, et al. CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer 2005;116:267-74.
28. Healey CS, Dunning AM, Durocher F, et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000;21:189-93.
29. Baxter SW, Choong DY, Eccles DM, et al. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001;22:347-9.
30. Haiman CA, Stram DO, Pike MC, et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003;12:2679-92.
31. Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071-82.
32. Labrie F, Luu-The V, Lin SX, et al. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000;25:1-16.
33. Setiawan VW, Hankinson SE, Colditz GA, et al. HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:213-19.
34. Normand T, Narod S, Labrie F, et al. Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. Hum Mol Genet 1993;2:479-83.
35. Kraft P, Pharoah P, Chanock SJ, et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet 2005; 1:e68.
36. American Cancer Society. Cancer facts & figures 2006. Atlanta, GA: American Cancer Society, 2006. (http://www. cancer.org/downloads/STT/ CAFF2006PWSecured.pdf).
37. Burke TW, Eifel PJ, Muggia FM. Cancer of the uterine body. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology. Philadelphia, PA: Lippincott, 2001.
38. Sherman ME, Carreon JD, Lacey JV Jr, et al. Impact of hysterectomy on endometrial carcinoma rates in the United States. J Natl Cancer Inst 2005;97:1700-2.
39. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
40. Herrinton LJ, Weiss NS. Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 1993;3:308-18.
41. Cushing KL, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol 1998;91:35-9.
42. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
43. Parazzini F, La Vecchia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16.
44. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
45. Persson I, Adami HO. Endometrial cancer. In: Adami HO, Hunter D, Trichopolos D, eds. Textbook of cancer epidemiology. New York, NY: Oxford University Press, 2002.
46. Weight control and physical activity. IARC handbooks of cancer prevention. Vol 6. Lyon, France: International Agency for Research on Cancer, World Health Organization, 2002.
47. Cauley JA, Gutai JP, Kuller LH, et al. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-31.
48. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87: 1297-302.
49. Verkasalo PK, Thomas HV, Appleby PN, et al. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom). Cancer Causes Control 2001;12:47-59.
50. Madigan MP, Troisi R, Potischman N, et al. Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes Control 1998;9:199-207.
51. Kelloff GJ, Lubet RA, Lieberman R, et al. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1998;7:65-78.
52. Tchernof A, Despres JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 2000;32:526-36.
53. Austin H, Drews C, Partridge EE. A case-control study of endometrial cancer in relation to cigarette smoking, serum estrogen levels, and alcohol use. Am J Obstet Gynecol 1993; 169:1086-91.
54. Somner J, McLellan S, Cheung J, et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2004;89:344-51.
55. Chacko P, Rajan B, Mathew BS, et al. CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer 2004;11:380-8.
56. Gharani N, Waterworth DM, Williamson R, et al. 5′ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. (Letter). J Clin Endocrinol Metab 1996;81:4174.
57. Riancho JA, Zarrabeitia MT, Valero C, et al. Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density. Bone 2005;36:917-25.
58. Small CM, Marcus M, Sherman SL, et al. CYP17 genotype predicts serum hormone levels among pre-menopausal women. Hum Reprod 2005;20:2162-7.
59. Haiman CA, Hankinson SE, Spiegelman D, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999;59: 1015-20.
60. Berstein LM, Imyanitov EN, Gamajunova VB, et al. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett 2002;180:47-53.
61. Berstein LM, Imyanitov EN, Suspitsin EN, et al. CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol 2001;127:135-8.
62. Daneshmand S, Weitsman SR, Navab A, et al. Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C(17-20) lyase promoters. Fertil Steril 2002;77:274-80.
63. Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6: 397-402.
64. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, et al. Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000;73: 735-41.
65. Garcia-Closas M, Herbstman J, Schiffman M, et al. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 2002;102:172-8.
66. Gaasenbeek M, Powell BL, Sovio U, et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab 2004;89:2408-13.
67. Zheng W, Gao YT, Shu XO, et al. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13: 709-14.
68. Feigelson HS, Shames LS, Pike MC, et al. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-7.
69. Hong CC, Thompson HJ, Jiang C, et al. Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer. Breast Cancer Res Treat 2004;88:217-30.
70. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
71. Haiman CA, Hankinson SE, Colditz GA, et al. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001;61:3955-60.
72. Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13: 94-101.
73. Kahsar-Miller M, Boots LR, Bartolucci A, et al. Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertil Steril 2004;82:973-5.
74. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, et al. Polymorphism T→C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999; 71:431-5.
75. Marszalek B, Lacinski M, Babych N, et al. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2001;15:123-8.
76. Lurie G, Maskarinec G, Kaaks R, et al. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1521-7.
77. Travis RC, Churchman M, Edwards SA, et al. No association of polymorphisms in CYP17, CYP19, and HSD17-B1 with plasma estradiol concentrations in 1,090 British women. Cancer Epidemiol Biomarkers Prev 2004;13:2282-4.
78. Berstein LM, Imyanitov EN, Kovalevskij AJ, et al. CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett 2004;207:191-6.
79. Aban M, Arslan M, Tok E, et al. CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer. Int J Gynecol Cancer 2006;16(suppl 1):448-51.
80. Szyllo K, Smolarz B, Romanowicz-Makowska H, et al. The polymorphisms of the CYP17 and CYP19 genes in endometrial cancer patients. Pol J Pathol 2006;57:35-40.
81. McKean-Cowdin R, Feigelson HS, Pike MC, et al. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res 2001;61:848-9.
82. Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-10.
83. Salmen T, Heikkinen AM, Mahonen A, et al. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women. Ann Med 2003;35:282-8.
84. Dick IM, Devine A, Prince RL. Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women. Am J Physiol Endocrinol Metab 2005;288:E989-95.
85. Probst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6: 165-73.
86. Baghaei F, Rosmond R, Westberg L, et al. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women. Obes Res 2003;11:578-85.
87. Miyoshi Y, Ando A, Hasegawa S, et al. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 2003;39: 2531-7.
88. Petry CJ, Ong KK, Michelmore KF, et al. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005;20:1837-43.
89. Sharp L, Cardy AH, Cotton SC, et al. CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors: a HuGE review. Am J Epidemiol 2004;160: 729-40.
90. Conley AJ, Bird IM. The role of cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Biol Reprod 1997;56:789-99.
91. Brock BJ, Waterman MR. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. Biochemistry 1999; 38:1598-606.